Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis

2006 ◽  
Vol 20 (3) ◽  
pp. 67-68
Author(s):  
Rainer H. Straub ◽  
Peter Harle ◽  
Seizo Yamana ◽  
Takemasa Matsuda ◽  
Kiyoshi Takasugi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Interleukin 6 ◽  
Antibody Therapy ◽  
Adrenal Androgen ◽  
Receptor Antibody ◽  
Interleukin 6 Receptor ◽  
Androgen Secretion

scholarly journals Anti-Interleukin-6 Receptor Antibody Therapy-Induced Retinopathy in a Patient with Rheumatoid Arthritis

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Asumi Tada ◽  
Noriyasu Hashida ◽  
Toshio Tanaka ◽  
Kohji Nishida
Keyword(s):  
Rheumatoid Arthritis ◽  
Interleukin 6 ◽  
Antibody Therapy ◽  
Common Adverse Event ◽  
Upper Respiratory Tract ◽  
Current Case ◽  
Cotton Wool Spots ◽  
Ocular Side ◽  
Interleukin 6 Receptor ◽  
Autoimmune Conditions

Tocilizumab, a humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody, is beneficial for treating autoimmune conditions such as rheumatoid arthritis (RA). The most common adverse event is upper respiratory tract infection; ocular side effects are rare. We describe a case of skin ulceration and bilateral retinopathy with multifocal cotton-wool spots and retinal hemorrhages in a patient with RA treated with tocilizumab. Tocilizumab administration increased the serum level of IL-6 without affecting the IL-8 levels. We could not exclude the possibility of blood coagulation or retinal vascular changes caused by tocilizumab. The current case highlights the need to consider that ocular adverse effects can develop in patients treated with tocilizumab.

scholarly journals Effects of Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, on Serum Lipid and Adipokine Levels in Patients with Rheumatoid Arthritis

2019 ◽  
Vol 20 (18) ◽  
pp. 4633 ◽  
Author(s):  
Elinoar Hoffman ◽  
Michal A. Rahat ◽  
Joy Feld ◽  
Muna Elias ◽  
Itzhak Rosner ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Lipid Profile ◽  
Interleukin 6 ◽  
Density Lipoprotein ◽  
High Sensitivity ◽  
Mechanistic Explanation ◽  
Receptor Antibody ◽  
Increased Risk ◽  
Interleukin 6 Receptor

Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease. Dyslipidemia is a known adverse effect of tocilizumab (TCZ), an anti-interleukin-6 receptor antibody used in RA treatment. We aimed to assess the effect of TCZ on lipid profile and adipokine levels in RA patients. Height, weight, disease activity scores, lipid profile and atherogenic indices (AI), leptin, adiponectin, resistin, interleukin-6, and high-sensitivity C-reactive protein (CRP) were measured before and four months after initiation of TCZ in 40 RA patients and 40 healthy controls. Following TCZ treatment, total cholesterol, high density lipoprotein (HDL), and triglycerides were significantly elevated, but no significant changes in weight, body mass index (BMI), low density lipoprotein (LDL), and AI were observed. Compared with controls, significantly higher adiponectin levels were measured in the RA group at baseline. Following TCZ treatment, resistin levels and the leptin-to-adiponectin ratio increased, adiponectin levels decreased, and leptin levels remained unchanged. No correlation was found between the change in adipokine serum levels and changes in the disease activity indices, nor the lipid profile. In conclusion, the changes observed suggest a protective role for TCZ on the metabolic and cardiovascular burden associated with RA, but does not provide a mechanistic explanation for this phenomenon.

Uneventful splenectomy and cholecystectomy in a patient treated with anti-interleukin-6 receptor antibody therapy

2007 ◽  
Vol 393 (3) ◽  
pp. 423-425
Author(s):  
Morihiko Ishizaki ◽  
Tetsuro Sasada ◽  
Akane Kunitomi ◽  
Yoshiteru Konaka ◽  
Masato Yagita ◽  
...  
Keyword(s):  
Interleukin 6 ◽  
Antibody Therapy ◽  
Receptor Antibody ◽  
Interleukin 6 Receptor
Sign in / Sign up

Export Citation Format

Share Document